Acceleron Inks $498M Pact with Shire for Lead Muscle Drug

Acceleron partners with Shire to develop its muscle enhancing drug, ACE-031, currently in a Phase IIa efficacy trial for Duchenne Muscular Dystrophy. ACE-031 acts by inhibiting the activin receptor type IIB and may preserve muscle strength in a broad category of muscle wasting diseases including ALS. This therapeutic target may even extend survival, as suggested by a related drug study in a mouse model of cachexia (see Nature News:

Click here to read more.

Share this: